In another study, neoadjuvant chemotherapy was associated with a higher rate of pathological complete response in BRCA1 and BRCA2 carriers than in other patients with triple-negative breast cancer.15 This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.